IL161104A0 - Small organic molecule regulators of cell proliferation - Google Patents

Small organic molecule regulators of cell proliferation

Info

Publication number
IL161104A0
IL161104A0 IL16110402A IL16110402A IL161104A0 IL 161104 A0 IL161104 A0 IL 161104A0 IL 16110402 A IL16110402 A IL 16110402A IL 16110402 A IL16110402 A IL 16110402A IL 161104 A0 IL161104 A0 IL 161104A0
Authority
IL
Israel
Prior art keywords
cell proliferation
organic molecule
small organic
molecule regulators
regulators
Prior art date
Application number
IL16110402A
Other languages
English (en)
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Publication of IL161104A0 publication Critical patent/IL161104A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IL16110402A 2001-09-26 2002-09-18 Small organic molecule regulators of cell proliferation IL161104A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/964,276 US6683192B2 (en) 2000-03-30 2001-09-26 Small organic molecule regulators of cell proliferation
PCT/US2002/029522 WO2003027234A2 (en) 2001-09-26 2002-09-18 Small organic molecule regulators of cell proliferation

Publications (1)

Publication Number Publication Date
IL161104A0 true IL161104A0 (en) 2004-08-31

Family

ID=25508346

Family Applications (3)

Application Number Title Priority Date Filing Date
IL16110402A IL161104A0 (en) 2001-09-26 2002-09-18 Small organic molecule regulators of cell proliferation
IL161104A IL161104A (en) 2001-09-26 2004-03-25 Small organic molecules that regulate cell culture
IL228106A IL228106A0 (en) 2001-09-26 2013-08-25 Small organic molecules that regulate cell culture

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL161104A IL161104A (en) 2001-09-26 2004-03-25 Small organic molecules that regulate cell culture
IL228106A IL228106A0 (en) 2001-09-26 2013-08-25 Small organic molecules that regulate cell culture

Country Status (19)

Country Link
US (1) US6683192B2 (zh)
EP (1) EP1436287A4 (zh)
JP (1) JP4563028B2 (zh)
KR (2) KR101039198B1 (zh)
CN (1) CN1578779B (zh)
AU (1) AU2002336580B2 (zh)
BR (1) BR0212825A (zh)
CA (1) CA2461709A1 (zh)
EA (1) EA200400355A1 (zh)
GE (1) GEP20063855B (zh)
HU (1) HUP0402307A2 (zh)
IL (3) IL161104A0 (zh)
MX (1) MXPA04002880A (zh)
NO (1) NO20041260L (zh)
NZ (1) NZ531970A (zh)
PL (1) PL371343A1 (zh)
UA (1) UA78225C2 (zh)
WO (1) WO2003027234A2 (zh)
ZA (1) ZA200402322B (zh)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7671200B2 (en) 1999-10-27 2010-03-02 Cytokinetics, Inc. Quinazolinone KSP inhibitors
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US6683108B1 (en) * 2000-03-30 2004-01-27 Curis, Inc. Agonists of hedgehog signaling pathways and uses related thereto
US20030220341A1 (en) * 2001-12-21 2003-11-27 Gary Bridger Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7354932B2 (en) * 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US6924376B2 (en) 2002-04-17 2005-08-02 Cytokinetics, Inc. Compounds, compositions and methods
CN100491358C (zh) 2002-05-09 2009-05-27 赛特凯恩蒂克公司 嘧啶酮类化合物、组合物及方法
US7361368B2 (en) 2002-06-28 2008-04-22 Advanced Cardiovascular Systems, Inc. Device and method for combining a treatment agent and a gel
US7390659B2 (en) 2002-07-16 2008-06-24 The Trustees Of Columbia University In The City Of New York Methods for inducing differentiation of embryonic stem cells and uses thereof
US20040224302A1 (en) * 2002-07-16 2004-11-11 Thomas Jessel Systems and methods for screening for modulators of neural differentiation
US7632679B2 (en) * 2002-07-16 2009-12-15 The Trustees Of Columbia University In The City Of New York Systems and methods for screening for modulators of neural differentiation
FR2842422B1 (fr) * 2002-07-16 2006-06-30 Univ Aix Marseille Ii Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
ATE423110T1 (de) 2002-07-17 2009-03-15 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
US7641643B2 (en) * 2003-04-15 2010-01-05 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
CA2547338A1 (en) * 2003-12-19 2005-07-07 Curis, Inc. Composition and methods for modulating cns activity
CN102964294A (zh) 2004-09-02 2013-03-13 遗传技术研究公司 Hedgehog信号转导的吡啶基抑制剂
WO2006039569A1 (en) * 2004-09-30 2006-04-13 The University Of Chicago Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents
US20060165739A1 (en) * 2005-01-06 2006-07-27 Mary Kay Inc. Alcohol-free microemulsion composition
US8828433B2 (en) 2005-04-19 2014-09-09 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
US8303972B2 (en) 2005-04-19 2012-11-06 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
US20080125745A1 (en) 2005-04-19 2008-05-29 Shubhayu Basu Methods and compositions for treating post-cardial infarction damage
US9539410B2 (en) 2005-04-19 2017-01-10 Abbott Cardiovascular Systems Inc. Methods and compositions for treating post-cardial infarction damage
US8187621B2 (en) 2005-04-19 2012-05-29 Advanced Cardiovascular Systems, Inc. Methods and compositions for treating post-myocardial infarction damage
WO2007025177A2 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2007089669A2 (en) * 2006-01-26 2007-08-09 Wyeth Processes for the preparation of compounds which modulate cell proliferation
EP1986622B1 (en) * 2006-02-15 2013-10-02 Dendreon Corporation Small-molecule modulators of trp-p8 activity
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20070244143A1 (en) * 2006-03-08 2007-10-18 Braincells, Inc Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
US9242005B1 (en) 2006-08-21 2016-01-26 Abbott Cardiovascular Systems Inc. Pro-healing agent formulation compositions, methods and treatments
EP2066355A2 (en) * 2006-09-19 2009-06-10 Braincells, Inc. Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
JP5399255B2 (ja) * 2006-10-31 2014-01-29 アメリカ合衆国 スムースンドポリペプチドおよび使用方法
WO2008057468A1 (en) * 2006-11-02 2008-05-15 Curis, Inc. Small organic molecule regulators of cell proliferation
US20080194637A1 (en) * 2006-11-02 2008-08-14 Curis, Inc. Small organic molecule regulators of cell proliferation
US20080182859A1 (en) * 2006-11-02 2008-07-31 Curis, Inc. Small organic molecule regulators of cell proliferation
US9005672B2 (en) 2006-11-17 2015-04-14 Abbott Cardiovascular Systems Inc. Methods of modifying myocardial infarction expansion
US20080177389A1 (en) * 2006-12-21 2008-07-24 Rob Gene Parrish Intervertebral disc spacer
WO2009042646A1 (en) * 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
MX2010008207A (es) * 2008-01-29 2012-10-01 Novartis Ag Uso de agonistas de hedgehog en el tratamiento de desordenes relacionados con el musculo esqueletico.
US8969081B2 (en) * 2008-12-10 2015-03-03 The Trustees Of Columbia University In The City Of New York Caudal motor neuron derived from embryonic stem cells under conditions essentially free of any retinoid
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2012048275A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
US9708299B2 (en) 2011-01-03 2017-07-18 Genentech, Inc. Hedgehog antagonists having zinc binding moieties
GB201201298D0 (en) 2012-01-26 2012-03-07 Universitat Leipzig Therapeutic use of activators of zinc finger protein gli3
US9248128B2 (en) 2012-01-27 2016-02-02 New York University Method for enhancing remyelination using GLI1 inhibitors
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MY175778A (en) 2013-10-04 2020-07-08 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9814703B2 (en) 2013-11-14 2017-11-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of BMP signaling
WO2015073913A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
WO2016049421A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled feed
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2016142427A1 (en) 2015-03-10 2016-09-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Method ank kit for reprogramming somatic cells
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
CN105130978B (zh) * 2015-07-22 2017-11-21 中国人民解放军军事医学科学院基础医学研究所 一种化合物及其在帕金森疾病方面的应用
WO2017048702A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
US10953003B2 (en) 2015-12-14 2021-03-23 X4 Pharmaceuticals, Inc. Methods for treating cancer
CA3008279A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
SI3393468T1 (sl) 2015-12-22 2023-01-31 X4 Pharmaceuticals, Inc. Postopki za zdravljenje bolezni imunske pomanjkljivosti
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3464565A4 (en) 2016-05-25 2020-01-01 Terumo BCT, Inc. CELL EXPANSION
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3808748A1 (en) 2016-06-21 2021-04-21 X4 Pharmaceuticals, Inc. Substituted piperidines as cxcr4-inhibitors
US11332470B2 (en) 2016-06-21 2022-05-17 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
JP7084624B2 (ja) 2016-06-21 2022-06-15 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
MX2019007890A (es) 2016-12-30 2020-01-20 Frequency Therapeutics Inc Compuestos de 1h-pirrol-2,5-diona y metodos de uso de los mismos para inducir la auto-renovacion de celulas madre/progenitoras de soporte.
US11529391B2 (en) * 2017-01-09 2022-12-20 The Board Of Trustees Of The Leland Stanford Junior University Reversing deficient hedgehog signaling restores deficient skeletal regeneration
EP3656842A1 (en) 2017-03-31 2020-05-27 Terumo BCT, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
WO2019048898A1 (en) 2017-09-05 2019-03-14 INSERM (Institut National de la Santé et de la Recherche Médicale) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION
WO2019146670A1 (ja) * 2018-01-24 2019-08-01 国立大学法人東京大学 光応答性Ｓｍｏｏｔｈｅｎｅｄリガンド
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
KR20210105899A (ko) 2018-11-19 2021-08-27 뉴욕 유니버시티 치료제로서의 GLi 1 억제제
WO2020106755A1 (en) 2018-11-19 2020-05-28 New York University Inhibitors of gli1 as therapeutic agents
CN112898178A (zh) * 2021-01-25 2021-06-04 蚌埠产品质量监督检验研究院 一种N-Boc-反式-1,4-环己二胺的制备方法
JP2024511064A (ja) 2021-03-23 2024-03-12 テルモ ビーシーティー、インコーポレーテッド 細胞捕獲及び増殖

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3612974A1 (de) * 1986-04-17 1987-10-29 Basf Ag 1,4-cyclohexandiamine, verfahren zu ihrer herstellung und ihre verwendung als fungizide
IL96019A0 (en) * 1989-10-31 1991-07-18 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
JPH0625250A (ja) * 1992-07-13 1994-02-01 Tooa Eiyoo Kk チエノ〔３，４−ｄ〕イミダゾール誘導体、その製造法およびそれを含有する循環器官用剤
WO1994013666A1 (en) * 1992-12-07 1994-06-23 Eisai Co., Ltd. Process for producing imidazopyridine derivative and intermediate
DE4326344A1 (de) * 1993-08-05 1995-02-09 Thomae Gmbh Dr K Carbonamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6281332B1 (en) * 1994-12-02 2001-08-28 The Johns Hopkins University School Of Medicine Hedgehog-derived polypeptides
CA2302780A1 (en) * 1997-08-29 1999-03-04 Ontogeny, Inc. Regulation of muscle tissues by hedgehog-like polypeptides, and formulations and uses related thereto
KR20010041656A (ko) * 1998-03-05 2001-05-25 개리 이. 프라이드만 비-펩타이드 성선자극호르몬-방출 호르몬 제제
US6291516B1 (en) * 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
IL146006A0 (en) * 1999-05-17 2002-07-25 Novo Nordisk As Glucagon antagonists/inverse agonists
US6545005B1 (en) * 1999-09-16 2003-04-08 Curtis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
CA2388468C (en) * 1999-10-14 2011-01-25 Curis, Inc. Mediators of hedgehog signalling pathways, compositions and uses related thereto
DE60113823T3 (de) * 2000-03-30 2010-07-01 Curis, Inc., Cambridge Kleine organische moleküle als regulatoren der zellproliferation

Also Published As

Publication number Publication date
IL228106A0 (en) 2013-09-30
ZA200402322B (en) 2005-06-23
CN1578779B (zh) 2013-09-18
EP1436287A2 (en) 2004-07-14
KR20040045003A (ko) 2004-05-31
KR20100105784A (ko) 2010-09-29
US6683192B2 (en) 2004-01-27
NZ531970A (en) 2006-11-30
GEP20063855B (en) 2006-06-26
EP1436287A4 (en) 2005-10-26
WO2003027234A2 (en) 2003-04-03
EA200400355A1 (ru) 2005-06-30
BR0212825A (pt) 2005-05-10
JP4563028B2 (ja) 2010-10-13
HUP0402307A2 (hu) 2005-02-28
CN1578779A (zh) 2005-02-09
NO20041260L (no) 2004-05-26
MXPA04002880A (es) 2005-06-20
PL371343A1 (en) 2005-06-13
US20020198236A1 (en) 2002-12-26
CA2461709A1 (en) 2003-04-03
KR101039198B1 (ko) 2011-06-03
WO2003027234A3 (en) 2003-12-18
AU2002336580B2 (en) 2008-10-30
IL161104A (en) 2013-08-29
KR101051535B1 (ko) 2011-07-22
WO2003027234A9 (en) 2004-02-19
JP2005520788A (ja) 2005-07-14
UA78225C2 (en) 2007-03-15
NO20041260D0 (no) 2004-03-25

Similar Documents

Publication Publication Date Title
IL228106A0 (en) Small organic molecules that regulate cell culture
WO2003065183A8 (en) Portable wireless access to computer-based systems
ZA200500041B (en) Novel condensated imidazole derivatives
TW587801U (en) Holder structure of portable keyboard
GB0417192D0 (en) Portable terminal
IL163959A0 (en) Small molecule entry inhibitors
AU2003283248A8 (en) Extremely thin substrate support
EP1279872A4 (en) SMALL PORTABLE INSTRUMENT
GB2392746B (en) Comparison of molecules using field points
TW570318U (en) Antenna supporting architecture
TW556829U (en) Rapid positioning structure of compasses
TW527072U (en) Arbitrary positioning pivot structure
TW512752U (en) Purifier of organic compounds
TW562255U (en) Antenna positioning structure
AU2002237186A1 (en) Cell proliferation factor fwa267
AU2002237184A1 (en) Cell proliferation factor fwap10576
AU2002368269A1 (en) Portable terminal
TW517515U (en) Structure of portable cultivation live-bottle
AU2003210651A1 (en) Portable wireless access to computer-based systems
GB0208105D0 (en) Support for binoculars
AU2002950195A0 (en) Cover support structure
GB0121477D0 (en) Regulator molecules
GB0208061D0 (en) Organic molecules
GB0216516D0 (en) Organic Molecules
TW580235U (en) Carrying base structure